OnKure Therapeutics (OKUR) Projected to Post Earnings on Thursday

OnKure Therapeutics (NASDAQ:OKUR) is expected to announce its results before the market opens on Thursday, November 6th. Analysts expect the company to announce earnings of ($1.19) per share for the quarter.

OnKure Therapeutics (NASDAQ:OKUR) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($1.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.23) by $0.09. On average, analysts expect OnKure Therapeutics to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

OnKure Therapeutics Stock Performance

Shares of OKUR stock opened at $3.19 on Thursday. The stock has a fifty day moving average price of $2.78 and a 200 day moving average price of $2.56. The stock has a market cap of $43.16 million, a PE ratio of -0.66 and a beta of 0.43. OnKure Therapeutics has a 1 year low of $1.70 and a 1 year high of $17.83.

Wall Street Analyst Weigh In

OKUR has been the subject of a number of research analyst reports. Zacks Research cut OnKure Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 13th. Weiss Ratings reissued a “sell (e+)” rating on shares of OnKure Therapeutics in a research note on Wednesday, October 8th. Finally, HC Wainwright restated a “buy” rating and set a $34.00 target price on shares of OnKure Therapeutics in a report on Tuesday, August 26th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $32.33.

Institutional Trading of OnKure Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in OKUR. Shay Capital LLC boosted its stake in shares of OnKure Therapeutics by 417.8% during the second quarter. Shay Capital LLC now owns 782,046 shares of the company’s stock valued at $1,869,000 after acquiring an additional 631,008 shares during the last quarter. Rangeley Capital LLC acquired a new position in OnKure Therapeutics in the 2nd quarter valued at about $71,000. Finally, XTX Topco Ltd purchased a new position in OnKure Therapeutics in the 2nd quarter valued at about $25,000. 90.98% of the stock is currently owned by hedge funds and other institutional investors.

OnKure Therapeutics Company Profile

OnKure Therapeutics, Inc engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer.